S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
NASDAQ:BEAM

Beam Therapeutics (BEAM) Stock Price, News & Analysis

$33.99
+0.45 (+1.34%)
(As of 02/23/2024 ET)
Today's Range
$33.28
$34.66
50-Day Range
$23.46
$33.54
52-Week Range
$16.95
$41.07
Volume
1.01 million shs
Average Volume
1.29 million shs
Market Capitalization
$2.77 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$43.92

Beam Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.38 Rating Score
Upside/​Downside
29.2% Upside
$43.92 Price Target
Short Interest
Bearish
16.43% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.26mentions of Beam Therapeutics in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$1.62 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.81) to ($4.54) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.68 out of 5 stars

Medical Sector

674th out of 939 stocks

Biological Products, Except Diagnostic Industry

120th out of 159 stocks


BEAM stock logo

About Beam Therapeutics Stock (NASDAQ:BEAM)

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 and BEAM-102 for the treatment of sickle cell disease beta thalassemia; BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease; and the Institute of Molecular and Clinical Ophthalmology Basel for treatment of impaired vision and blindness. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

BEAM Stock Price History

BEAM Stock News Headlines

Analysts see over 50% gains in these 2 mid-cap biotech stocks
In recent years, emergency Covid vaccines have ushered in several groundbreaking innovations that have changed the way drugs are developed and health care is administered. Advancements in the treatment of cancer, Alzheimer's disease and obesity have highlighted steady progress in the field.
Analysts see over 50% gains in these 2 mid-cap biotech stocks (BEAM)
The outlook for growth has made biotech one of the hottest investments of late - and Wall Street sees big comeback gains ahead in these two biotechs.
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024.
The same catalyst the kicked off the three major crypto bull markets... is about to hit again on April 22, 2024
2 gene editing stocks to keep on your 2024 watchlist (BEAM)
Gene therapy is receiving much of the spotlight in the medical sector in 2024. The FDA approval for Casgevy, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX)
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN?
Financial giants have been injecting millions into the crypto market. The big players are going all in on crypto… but what are they gearing up for? There is a significant event on the horizon that will shape the future of Bitcoin—the upcoming Bitcoin halving event…We're revealing all the secrets behind the financial elite's bold moves in crypto during our LIVE, online event.
Beam Therapeutics Inc
BofA gets more bearish on Beam Therapeutics, downgrades shares
See More Headlines
Receive BEAM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Beam Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2023
Today
2/23/2024
Next Earnings (Estimated)
2/27/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:BEAM
Fax
N/A
Employees
439
Year Founded
2017

Price Target and Rating

Average Stock Price Target
$43.92
High Stock Price Target
$105.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+29.2%
Consensus Rating
Hold
Rating Score (0-4)
2.38
Research Coverage
13 Analysts

Profitability

Net Income
$-289,090,000.00
Net Margins
-384.62%
Pretax Margin
-383.39%

Debt

Sales & Book Value

Annual Sales
$60.92 million
Book Value
$10.41 per share

Miscellaneous

Free Float
77,918,000
Market Cap
$2.77 billion
Optionable
Optionable
Beta
1.66

Social Links

The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report














BEAM Stock Analysis - Frequently Asked Questions

Should I buy or sell Beam Therapeutics stock right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Beam Therapeutics in the last year. There are currently 8 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BEAM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BEAM, but not buy additional shares or sell existing shares.
View BEAM analyst ratings
or view top-rated stocks.

What is Beam Therapeutics' stock price target for 2024?

13 Wall Street research analysts have issued 12 month target prices for Beam Therapeutics' shares. Their BEAM share price targets range from $20.00 to $105.00. On average, they anticipate the company's share price to reach $43.92 in the next year. This suggests a possible upside of 29.2% from the stock's current price.
View analysts price targets for BEAM
or view top-rated stocks among Wall Street analysts.

How have BEAM shares performed in 2024?

Beam Therapeutics' stock was trading at $27.22 at the beginning of the year. Since then, BEAM stock has increased by 24.9% and is now trading at $33.99.
View the best growth stocks for 2024 here
.

When is Beam Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our BEAM earnings forecast
.

How were Beam Therapeutics' earnings last quarter?

Beam Therapeutics Inc. (NASDAQ:BEAM) posted its earnings results on Wednesday, November, 8th. The company reported ($1.22) earnings per share for the quarter, beating analysts' consensus estimates of ($1.33) by $0.11. The company earned $17.20 million during the quarter, compared to analyst estimates of $17.09 million. Beam Therapeutics had a negative net margin of 384.62% and a negative trailing twelve-month return on equity of 40.66%. The company's revenue for the quarter was up 8.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.56) earnings per share.

What other stocks do shareholders of Beam Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Beam Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Editas Medicine (EDIT), Cisco Systems (CSCO), Block (SQ), Skyworks Solutions (SWKS), Akoustis Technologies (AKTS), Invitae (NVTA), QUALCOMM (QCOM) and Alector (ALEC).

When did Beam Therapeutics IPO?

(BEAM) raised $101 million in an initial public offering (IPO) on Thursday, February 6th 2020. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies and Barclays acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Beam Therapeutics' major shareholders?

Beam Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include ARK Investment Management LLC (11.53%), Vanguard Group Inc. (8.79%), Sumitomo Mitsui Trust Holdings Inc. (2.89%), Nikko Asset Management Americas Inc. (2.89%), Baillie Gifford & Co. (0.94%) and Northern Trust Corp (0.82%). Insiders that own company stock include Amy Simon, Christine Bellon, Fmr Llc, Giuseppe Ciaramella, Graham K Cooper, John M Evans, John M Evans and Terry-Ann Burrell.
View institutional ownership trends
.

How do I buy shares of Beam Therapeutics?

Shares of BEAM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Beam Therapeutics have any subsidiaries?
The following companies are subsidiares of Beam Therapeutics: Blink Therapeutics Inc..
Read More
This page (NASDAQ:BEAM) was last updated on 2/23/2024 by MarketBeat.com Staff